Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak

Key Findings & Data:Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans.

💡

Conclusion & Impact:In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Abstract: Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists, and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered to children with CP with appropriate indications and with necessary precautions during the pandemic.Key words: Botulinum toxin, cerebral palsy, COVID-19, pandemic, spasticity

🔖

Cite This Article

AKPINAR, P., AKYÜZ, E. Ü., TIKIZ, C., KUTLAY, Ş., TUR, B. S., ÇAPAN, N., ÇAĞLAR, S., ZİNNUROĞLU, M., YALÇINKAYA, E. Y., İÇAĞASIOĞLU, A., MISIRLIOĞLU, T. Ö., TEKİN, S., HÜNER, B., SEZGİN, M., ÖNEŞ, K., TAŞKIRAN, Ö. Ö., OFLUOĞLU, D., AKPINAR, P. (2022). Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 2, 385–392. https://ajindex.com/articles/609874

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Dy R, Roge D. Medical updates in management of hypertonia. Physical Medicine and Rehabilitation Clinics of North America 2020; 31 (1): 57-68. doi: 10.1016/j.pmr.2019.09.010 2. Reebye R, Finlayson H, May C, Satkunam L, Wein T et al. Practical guidance for outpatient spasticity management during the coronavirus (COVID-19) pandemic: canadian spasticity COVID-19 task force. Canadian Journal of Neurological Sciences 2020; 1-17. doi: 10.1017/cjn.2020.104 3. Baricich A, Santamato A, Picelli A, Morone G, Smania N et al. Spasticity treatments during COVID-19 pandemic: clinical recommendations. Frontiers in Neurology 2020; 11: 719. doi: 10.3389/fneur.2020.00719 4. Blumetti FC, Belloti JC, Tamaoki MJ, Pinto JA. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cochrane Database Systematic Reviews. 2019; 10(10): CD001408. doi: 10.1002/14651858.CD001408 5. Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. Journal of Parkinsons Disease 2020; 10 (2): 351-354. doi: 10.3233/JPD-202038 6. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatric Pulmonology 2020; 55 (5): 1169-1174. doi: 10.1002/ppul.24718 7. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World Journal of Pediatrics 2020; 16 (3): 240-246. doi: 10.1007/s12519-020- 00345-5 8. Shen KL, Yang YH, Jiang RM, Wnag TY, Zhao DC et al. Updated diagnosis, treatment and prevention of covid-19 in children: experts’ consensus statement (condensed version of the second edition). World Journal of Pediatrics 2020; 16 (3): 232-239. doi: 10.1007/s12519-020-00362-4 9. Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandao MB.Clinical manifestations of children with COVID-19: a systematic review. PediatricPulmonology 2020; 55 (8): 1892- 1899. doi10.1002/ppul.24885 10. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. Journal of Medical Virology 2020; 92: 747-754.doi: 10.1002/jmv.25807 11. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. Journal of American Medical Association Pediatrics 2020; 174 (9): 868- 873.